Introduction
Both acute and chronic hepatitis are seen in neonates and children, and both have at some time been considered responsive to immunosuppressive agents, particularly corticosteroids. Many conflicting reports have appeared regarding the usefulness of such therapy, but few adequately controlled trials have been performed. None of the reported trials has specifically involved children, although a few children and young adults have been included in some of these trials. This review covers the controlled trials that have taken place, assesses the results and the need for future trials in general and in children in particular. Three topics will be covered-acute viral hepatitis, active chronic hepatitis and neonatal hepatitis.
Acute viral hepatitis
Acute viral hepatitis is a common, but usually extremely mild gastrointestinal infection in childhood. In 1971 only eighteen deaths occurred in Great Britain from this disease in the under 14 agegroup, compared to 2607 cases notified (RegistrarGeneral, 1971 ). Many early trials using ACTH or corticosteroids gave conflicting results, and none was specifically performed in children. Evans, Spring and Nelson (1953) reported a study in which patients were treated with ACTH or placebo, and no difference in the rate of improvement between the two groups was seen. When cortisone was used, recovery was more rapid in the treated group but more patients relapsed. Sborov et al. (1954) found no difference in the rate of clinical or biochemical recovery between forty-nine patients treated with cortisone and thirtysix controls, and Ducci and Katz (1955) achieved similar results. Huber and Wylie (1955) found a more rapid improvement in patients treated with cortisone, but no statistics were presented. Naglo, Rydenstam and Silverstolpe (1959) found no difference in the rate of recovery between twenty-five patients treated with ACTH and twenty-five controls, and side-effects from ACTH were a serious problem. De Ritis et al. (1964) carried out a trial of prednisone 30 mg/day versus placebo, and no differences were found between the two groups with respect to rate of clinical or biochemical recovery, or duration of the disease. Vakil et al. (1965) Tygstrup (1969) has written that such trials would be unjustifiable.
Active chronic hepatitis
Active chronic hepatitis has characteristic pathological features (de Groote et al., 1968 ) and a poor prognosis, even with treatment, with cirrhosis as the end result (Mistilis and Blackburn, 1970) . As a disease believed to have an 'auto-immune' basis (Mackay, Taft and Cowling, 1956) , immunosuppressive therapy may be beneficial, and early reports (Page, Condie and Good, 1964; Cook, Velasco and Sherlock, 1970) suggested this to be the case. The disease may be seen in all age groups, and though there are a few differences between the childhood and adult diseases, e.g. the presence of microsomal antibodies in younger patients (Walker et al., 1973) , the evidence is that they are basically similar. Of ninety-four patients seen in the Liver Unit over a 4-year-period (Reed etal., 1973) 
Neonatal hepatitis
As discussed elsewhere in this symposium, neonatal hepatitis has a number of distinguishing features, of which one of the most characteristic is giant cell formation (Schaffner and Popper, 1963) .
The same clinical and pathological features may be seen in response to a number of different viruses, such as cytomegalovirus (Weller and Hanshaw, 1962) , herpes simplex (Pugh, Newns and Dudgeon, 1954) and congenital rubella (Stern and Williams, 1966) , may occur in congenital biliary atresia, and alpha-1-antitrypsin deficiency, but in most cases the cause is never found. The prognosis is extremely variable, and several reports (Stowens, 1966; ) have suggested that one-third die in the acute phase and one-third develop cirrhosis. Corticosteroids have been used (Nelson, 1969; but the results are conflicting. No controlled trials have been reported, and the need for one to be carried out is urgent. Such a trial should aim to answer the following questions.
(1) Does treatment with an immunosuppressive agent, e.g. prednisolone, significantly alter the mortality?
(2) Does treatment significantly reduce the incidence of cirrhosis?
(3) Do the benefits outweigh the side-effects for the series as a whole?
Since large numbers of patients (seventy-five to one hundred) would be needed to show any clear differences, a trial would either have to be carried out in a special referral centre, or on a multicentre basis. The first question could be answered fairly quickly, but the second would need at least a 2-year follow-up period on every patient. Patients would be assessed initially, and randomly allocated into a group treated with corticosteroids and a group given a placebo. The criteria for admission should be clinical (e.g. any child between 1-and 16-weeks-old with jaundice and abnormal liver function tests persisting for over 3 weeks) and pathological (e.g. liver biopsy appearances compatible with neonatal giant cell hepatitis) rather than aetiological.
The question of whether such a trial should be double-blind or not is difficult. As has been heard already, the dangers of giving steroids to children are considerable and most people would consider it preferable to know which children were receiving steroids and which were not. Furthermore, the important measurements to make will be the liver function tests, the presence or absence of cirrhosis on liver biopsy, and the mortality rate. Provided the pathologist looked at the liver biopsy specimens 'blind', these measurements are all objective, and the trial need not be conducted in a double-blind manner.
Straightforward statistical analyses may be performed, to compare the median survival time, the changes in liver function tests, and the proportion of patients developing cirrhosis, in each group. The probability of survival of a patient on steroids or on a placebo may be calculated by the life-table method (Bradford Hill, 1971 ).
Conclusions
It is now established that corticosteroids are of no benefit in uncomplicated viral hepatitis in childhood, although their role in fulminant hepatic failure is still controversial (Williams, 1972 
